Abstract:Essential thrombocytosis (ET) is a subtype of Bcr-Abl negative the chronic myeloproliferative disorders and the mutated JAK2V617F has been identified and correlated with ET. The aim of this study was to analyze the mutational status and quantitative expression of JAK2V617F mRNA transcripts in cohort of 98 Chinese patients with ET and to determine the disease features. The cohort consisted of 46 men and 52 women with median age at diagnosis was 50 years (range 17–87), granulocyte cDNA was enriched from blood samples obtained at the time of clinical assessment. A quantitative JAK2V617F measurements were made using amplification-refractory mutation sequencing polymerase chain reaction (ARMS-PCR) and capillary electrophoresis assay. Fifty-nine(60.2%) patients harboring the JAK2 V617F mutation were found, including 17 homozygous and 42 heterozygous changes. The quantitative assay by capillary electrophoresis showed that the mutated mRNA ratio was (89.9±6.7)% in the JAK2V617F homozygote and was (57.1±6.7)% in the JAK2V617F heterozygote patients, the difference was significant(P<0.005). JAK2V617F-positive ET patients were older than patients without the mutation (55 versus 38 years, p<0.001), and the patients whose age ≥ 60 years showed significantly higher JAK2 mutated RNA levels as compared to patients whose age ≤60 years(68.2% versus 80.2%, P =0.0056). Males and females had similar JAK2V617F prevalence (63.0% versus 57.7%) and frequency of homozygosity (17.4% versus 17.3%). As compared to heterozygous ET patients, higher leukocyte count was observed in homozygous ET patients (27.9×109/L versus 15.2×109/L, P©‚0.05), JAK2V617F-positive patients also had a higher median white cell count than wild-type patients (19.4×109/L versus 9.7×109/L, P©‚0.05), but there were no significant differences in hemoglobin concentration or platelet count. During follow-up, 30 patients suffered from documented thrombotic events, with 24 having JAK2V617F mutations. The rate of thrombotic complications in JAK2V617F-positive and homozygous patients was higher than in JAK2 wild-type and heterozygous patients, respectively. (52.2% versus 17.6%, 75% versus 32.8%, respectively ). Compared with patients without thrombotic events, there were higher levels of mutated JAK2 mRNA in patients with thrombotic events(76.9% versus 58.4%, P©‚0.05), thrombotic events were also significantly correlated with leukocytosis and older age. Our results suggest that there are different clinical features between JAK2V617F-positive and JAK2V617F-negative, homozygote and heterozygote, higher and lower levels of mutated JAK2 mRNA, and correlated with leukocytosis and thrombosis. Therefore, detection of the JAK2V617F mutational status and mutated JAK2 mRNA can help not only identify the disease state and progression, but also affect the management of ET patients.

Co-occurrence of CALR and JAK2 V617F mutations in essential thrombocythemia:report of two cases and review of literature

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

JAK2, MPL, and CALR Mutations in Chinese Han Patients with Essential Thrombocythemia.

A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia

Quantitative Analysis for Jak2 Mutation in 98 Patients with Essential Thrombocythemia and Its Clinical Significance

A Quantitive Assay and Clinical Significance for JAK2V617F Mutation in Chinese Patients with Essential Thrombocytosis

Frequency and Allele Burden of CALR Mutations in Chinese with Essential Thrombocythemia and Primary Myelofibrosis Without JAK2(V617F) or MPL Mutations.

Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation

Essential Thrombocythemia with CALR Mutation and Recurrent Stroke: Two Case Reports and Literature Review

[Comparison of Clinical Characteristics of JAK2, CALR and Tri-Negative Driving Mutant Type in Patients with Essential Thrombocythemia]

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia

Clinical Relevance Between CALR Mutation and Myeloproliferative Neoplasms.

JAK2 V617F Positive Essential Thrombocythemia Developing in a Patient with CD5⁻ Chronic Lymphocytic Leukemia.

The Mutation Profile of JAK2 and CALR in Chinese Han Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts.

Observation of a higher JAK2 V617F homozygous mutated clone in polycythemia vera compared to essential thrombocythemia

Triple Gene Detection of CALR, JAK2(V617F) or MPL(W515L/K) Mutation to Predict Thrombosis and Splenomegaly Risk in Essential Thrombocythemia and Primary Myelofibrosis Patients: A Systematic Review and Meta-Analysis

Clinical significance of JAK2,CALR and MPL gene mutations in 132 myeloproliferative neoplasms patients with BCR-ABL fusion gene negative

ASXL1 Mutations in Chinese Patients with Essential Thrombocythemia

The Clinical Implications of JAK2V617F Mutation in 137 Chinese Patients with Myeloproliferative Diseases.